iBio grants director Alexandra Kropotova 38,000 options

The options vest in monthly installments over twelve months, beginning one month after the grant and conditioned on continued service through each vesting date.

Rhea-AI Filing Summary

iBio, Inc. director Alexandra Kropotova received a direct grant of 38,000 stock options on October 14, 2026, covering 38,000 shares of common stock at an exercise price of $0.7800 per share. The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant, subject to her continued service through each applicable vesting date. They expire October 13, 2036.

Insider Trade Summary

Grant/Award: 38,000 shares

Grant/Award 1 txn

Insider Kropotova Alexandra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	38,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 38,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

Key Figures

Stock options granted: 38,000 options Underlying common stock: 38,000 shares Exercise price: $0.7800 per share +2 more

5 metrics

Stock options granted 38,000 options Direct grant on October 14, 2026

Underlying common stock 38,000 shares Shares covered by the options

Exercise price $0.7800 per share Price to exercise the options

Vesting period 12 months Monthly installments, with the first one month after the grant

Expiration date October 13, 2036 Option expiration

Key Terms

Stock Option (right to buy), pro rata, exercise price, vesting date

4 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

pro rata financial

"vest pro rata in monthly installments"

Pro rata means dividing or distributing something proportionally based on a specific factor, such as ownership or contribution. For example, if an investor owns 10% of a company, they would receive 10% of any dividends or benefits allocated. This approach ensures everyone gets their fair share relative to their stake or input, helping investors understand how benefits, costs, or responsibilities are fairly shared.

exercise price financial

"options at an exercise price of $0.7800 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting date financial

"through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did iBio (IBIO) director Alexandra Kropotova receive?

Alexandra Kropotova received a direct grant of 38,000 stock options covering 38,000 shares of common stock on October 14, 2026.

What is the exercise price for Alexandra Kropotova's iBio (IBIO) options?

The options have an exercise price of $0.7800 per share and expire October 13, 2036.

How do Alexandra Kropotova's iBio (IBIO) options vest?

They vest pro rata in monthly installments over twelve months. The first installment vests one month after the grant, subject to her continued service through each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 06:33 PM EDT Accepted by SEC EDGAR 10/15/2026 - 06:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kropotova Alexandra

(Last) (First) (Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$0.78	10/14/2026		A		38,000(1)		(1)	10/13/2036	Common Stock	38,000	$0	38,000	D

Explanation of Responses:

1. The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Marc Banjak, Attorney-in-fact	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)